Cody Parsons, APh, PharmD, BCCCP, says protected pharmacist access lets patients with heart failure be seen more often than typical clinic visits allow.
|Videos|September 17, 2015
Gaps in Pharmacy System's Support of Smoking Cessation
Lisa Kroon, PharmD, CDE, professor and department chairperson of clinical pharmacy at University of California, San Francisco, School of Pharmacy, talks about gaps in pharmacy systems' support of smoking cessation.
Advertisement
Lisa Kroon, PharmD, CDE, professor and department chairperson of clinical pharmacy at University of California, San Francisco, School of Pharmacy, talks about gaps in pharmacy systems' support of smoking cessation.
This video was recorded at the 2015 NACDS Total Store Expo.
Advertisement
Related to this article
Post hoc AHA 2026 data show the oral GLP-1 receptor agonist lowered systolic blood pressure across hypertension stages, partly beyond weight loss.
The evidence for GLP-1 receptor agonists keeps growing, while access for low-income patients keeps narrowing.
Specialty pharmacists can help patients with cancer weigh the benefits and risks of GLP-1 receptor agonists as use expands and new evidence emerges.
Pharmacists can work alongside dermatologists, nurses, and other health care professionals to help answer skin care–related questions and help patients understand trial outcomes.
Early metformin may curb insulin starts in gestational diabetes, while a separate analysis ties a history of the condition to advanced CKM syndrome.
Pharmacy Times previews enlicitide, survodutide, diet and heart failure risk, and pharmacist-led HF care ahead of the AHA Scientific Sessions in Chicago.
Expected in the first half of 2028, the planned separation would create a stand-alone retail pharmacy company with nearly 30,000 pharmacists.
Advertisement
Advertisement
Trending on Pharmacy Times
1
Understanding Kratom: Pharmacology, Safety, and Regulation
2
Orforglipron Lowers Systolic BP in ATTAIN-1, ATTAIN-2 Analyses
3
How Stanford Pharmacists Help Close Heart Failure Therapy Gaps
4
GLP-1s and Obesity Care: Cardiorenal Outcomes, Prescribing Considerations, and Access Barriers
5